Genetic counseling

Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO

Retrieved on: 
Tuesday, January 9, 2024
Myriad Genetics, Patient, SSO, Health, ASCO, Gene, Breast cancer, Society, Genetics, Surgical oncology, Genetic testing, Cancer, Genetic counseling, Genomics, Penetrance, MYGN, PARP, Guideline, Diagnosis, Medicine, Medical device

SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of Clinical Oncology (ASCO)—Society of Surgical Oncology (SSO) guideline for germline testing in patients with breast cancer.

Key Points: 
  • SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of Clinical Oncology (ASCO)—Society of Surgical Oncology (SSO) guideline for germline testing in patients with breast cancer.
  • Among the guidance includes:
    All patients with a current or previous diagnosis of invasive breast cancer ≤ 65 years should be offered BRCA1/2 testing.
  • Patients undergoing genetic testing should be given sufficient information before testing to provide informed consent.
  • “ASCO-SSO’s guideline update is an important step forward in advancing the use of genomics in clinical care for patients with breast cancer,” said Shelly Cummings, Vice President of Oncology Medical Affairs, Myriad Genetics.

Identifai-Genetics Launches Its First U.S. Clinical Trial, Led by Professor Ronald Wapner

Retrieved on: 
Thursday, January 11, 2024
Woman, Columbia, Assistant, Associate, DNA, Gynaecology, Birth, NIPT, Partnership, AI, Genetics, TEL, Pregnancy, Disease, Genetic counseling, Prevalence, Columbia University, Obstetrics, Anomaly, Parent, Clinical trial, Research, Fetus, Trial of the century

Identifai's platform and diagnostic tools enable early detection of the whole spectrum of fetal genetic disorders in an accessible, cost-effective and risk-free manner.

Key Points: 
  • Identifai's platform and diagnostic tools enable early detection of the whole spectrum of fetal genetic disorders in an accessible, cost-effective and risk-free manner.
  • Identifai's US clinical study is aimed at demonstrating the performance and effectiveness of the company's novel technology in real-world scenarios within the United States.
  • The principal investigator in the study is world-renowned Professor Ronald J. Wapner, Director of Reproductive Genetics and Professor of Obstetrics and Gynecology at Columbia University Irving Medical Center.
  • This study marks a critical milestone in transforming Identifai's technology into a clinical offering accessible to millions of women in the US and across the globe".

MotherToBaby Launches Spanish-Language Digital Health Website to Reach Underserved Latinx Communities in the U.S. & Canada

Retrieved on: 
Wednesday, January 10, 2024
Midwifery, Zolpidem, Research, Government, Pediatrics, Health, Genetics, FREE, Gynaecology, Teratology, Organization, Language, Risk, Public, HRSA, CDC, Pharmacy, Genetic counseling, Pregnancy, OTIS, Heel, COVID-19, HHS, Child, Obstetrics, Unitary state, Nursing, Parent, MPH, Attenuated vaccine, Vaccine, Birth, Birth control

BRENTWOOD, Tenn., Jan. 10, 2024 /PRNewswire-PRWeb/ -- ¿Hablas español? ¡Sí! In time for January's Birth Defects Awareness Month, MotherToBaby is proud to announce the launch of its fully bilingual (English/Spanish) website. It's the first of its kind for housing an extensive bilingual library of fact sheets on everything from alcohol to zolpidem during pregnancy and breastfeeding as well as connecting bilingual experts with parents and healthcare providers.

Key Points: 
  • In time for January's Birth Defects Awareness Month, MotherToBaby is proud to announce the launch of its fully bilingual ( English / Spanish ) website.
  • "No matter what the language they speak is, we want everyone to have access to the best, expert health information possible."
  • The now fully bilingual website is designed to fill the gap in the disparities of health education information for pregnant and breastfeeding individuals who are Spanish-speakers.
  • MotherToBaby wants to improve birth outcomes in the Latinx community by giving improved access to language-appropriate resources to families and health professionals.

American Kidney Fund Hosts Fourth National Summit on Unknown Causes of Kidney Disease

Retrieved on: 
Tuesday, December 5, 2023
Nephrology, Cardiology, Public policy, Genetic counseling, Food, Risk, Division, Research, Kidney disease, Vertex Pharmaceuticals, Health, Education, Legislation, Therapy, Columbia University, Focal segmental glomerulosclerosis, Kidney, COVID-19, Patient, Diagnosis, AKF, American Kidney Fund, Pharmaceutical industry

ROCKVILLE, Md., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) will convene more than 100 medical leaders, patient advocates and academic and industry leaders for the fourth national summit of its Unknown Causes of Kidney Disease (UCKD) Project, which seeks to improve understanding of how undiagnosed or misdiagnosed causes of kidney disease directly impact patient care and outcomes.

Key Points: 
  • ROCKVILLE, Md., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) will convene more than 100 medical leaders, patient advocates and academic and industry leaders for the fourth national summit of its Unknown Causes of Kidney Disease (UCKD) Project, which seeks to improve understanding of how undiagnosed or misdiagnosed causes of kidney disease directly impact patient care and outcomes.
  • This will be the first in-person summit after three years of virtual summits due to the pandemic.
  • This week’s summit, which will be held in Arlington, Virginia, will further explore how the kidney community can drive innovation in research, diagnosis and treatment of the underlying causes of kidney disease.
  • “Finding out the root cause of one’s kidney disease can bring crucial clinical insights to providers and have life-saving implications for individuals.

GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy

Retrieved on: 
Friday, December 1, 2023
Patient, Conference, Hospital, Seizure, Genetic counseling, Whole genome sequencing, Epilepsy, AES, American Epilepsy Society, Diet, National Society, DSM-IV codes, MD, Doctor of Philosophy, Research, Health, NSGC, Parent, Insurance, Test management, Genetic testing, FACMG, Medicaid, Diagnosis, Clinical, WGS, Michelle, GeneDx

The gap in diagnosis between exome sequencing and the multi-gene epilepsy panels can be largely attributed to the fact that more than half (57%) of seizure-related genes are not included on many commercially available epilepsy panels.

Key Points: 
  • The gap in diagnosis between exome sequencing and the multi-gene epilepsy panels can be largely attributed to the fact that more than half (57%) of seizure-related genes are not included on many commercially available epilepsy panels.
  • Of those patients with a positive genetic diagnosis from exome sequencing, 11% had a variant in a treatment related gene.
  • GeneDx will also present data at the conference that shows insurance may offer better coverage for exome sequencing than multi-gene panels for patients with epilepsy.
  • At the conference, GeneDx will also be hosting an industry sponsored symposium discussing the ways in which exome sequencing can help epilepsy patients find answers sooner.

International Center for Genetic Disease, Mass General Brigham launches a global Clinical Genomic Medicine and Genetic Counseling training program in United Arab Emirates

Retrieved on: 
Tuesday, November 21, 2023
Hospital, Genetic counseling, Partnership, Medicine, Physician, International Center, Prognosis, Excellency, Trustee, Diabetes, Emirate, Health, Doctor of Philosophy, Khalifa University, Cancer, Mass, Genomics, Knowledge, Genetics, Public, Mass General Brigham, DSM-IV codes, Harvard University, FACMG, Patient, Diagnosis, Risk management, Harvard Medical School, MSHA, Hemoglobinopathy, Pharmaceutical industry

To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.

Key Points: 
  • To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.
  • This training program is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology.
  • This initiative is designed to integrate genetics and genomics into patient care effectively, underscoring our dedication to enhancing genomic medicine worldwide.
  • Higgins, MD, MSHA, President of Brigham and Women’s Hospital and Executive Vice President at Mass General Brigham.

International Center for Genetic Disease, Mass General Brigham launches a global Clinical Genomic Medicine and Genetic Counseling training program in United Arab Emirates

Retrieved on: 
Tuesday, November 21, 2023
Hospital, Genetic counseling, Partnership, Medicine, Physician, International Center, Prognosis, Excellency, Trustee, Diabetes, Emirate, Health, Doctor of Philosophy, Khalifa University, Cancer, Mass, Genomics, Knowledge, Genetics, Public, Mass General Brigham, DSM-IV codes, Harvard University, FACMG, Patient, Diagnosis, Risk management, Harvard Medical School, MSHA, Hemoglobinopathy, Pharmaceutical industry

To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.

Key Points: 
  • To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.
  • This training program is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology.
  • This initiative is designed to integrate genetics and genomics into patient care effectively, underscoring our dedication to enhancing genomic medicine worldwide.
  • Higgins, MD, MSHA, President of Brigham and Women’s Hospital and Executive Vice President at Mass General Brigham.

International Center for Genetic Disease, Mass General Brigham launches a global Clinical Genomic Medicine and Genetic Counseling training program in United Arab Emirates

Retrieved on: 
Tuesday, November 21, 2023
Hospital, Genetic counseling, Partnership, Medicine, Physician, International Center, Prognosis, Excellency, Trustee, Diabetes, Emirate, Health, Doctor of Philosophy, Khalifa University, Cancer, Mass, Genomics, Knowledge, Genetics, Public, Mass General Brigham, DSM-IV codes, Harvard University, FACMG, Patient, Diagnosis, Risk management, Harvard Medical School, MSHA, Hemoglobinopathy, Pharmaceutical industry

To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.

Key Points: 
  • To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.
  • This training program is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology.
  • This initiative is designed to integrate genetics and genomics into patient care effectively, underscoring our dedication to enhancing genomic medicine worldwide.
  • Higgins, MD, MSHA, President of Brigham and Women’s Hospital and Executive Vice President at Mass General Brigham.

International Center for Genetic Disease, Mass General Brigham launches a global Clinical Genomic Medicine and Genetic Counseling training program in United Arab Emirates

Retrieved on: 
Tuesday, November 21, 2023
Hospital, Genetic counseling, Partnership, Medicine, Physician, International Center, Prognosis, Excellency, Trustee, Diabetes, Emirate, Health, Cancer, Doctor of Philosophy, Khalifa University, Mass, Genomics, Knowledge, Genetics, Public, Mass General Brigham, DSM-IV codes, Harvard University, FACMG, Patient, Diagnosis, Risk management, Harvard Medical School, MSHA, Hemoglobinopathy, Pharmaceutical industry

To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.

Key Points: 
  • To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.
  • This training program is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology.
  • This initiative is designed to integrate genetics and genomics into patient care effectively, underscoring our dedication to enhancing genomic medicine worldwide.
  • Higgins, MD, MSHA, President of Brigham and Women’s Hospital and Executive Vice President at Mass General Brigham.

International Center for Genetic Disease, Mass General Brigham launches a global Clinical Genomic Medicine and Genetic Counseling training program in United Arab Emirates

Retrieved on: 
Tuesday, November 21, 2023
Hospital, Genetic counseling, Partnership, Medicine, Physician, International Center, Prognosis, Excellency, Trustee, Diabetes, Emirate, Health, Doctor of Philosophy, Khalifa University, Cancer, Mass, Genomics, Knowledge, Genetics, Public, Mass General Brigham, DSM-IV codes, Harvard University, FACMG, Patient, Diagnosis, Risk management, Harvard Medical School, MSHA, Hemoglobinopathy, Pharmaceutical industry

To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.

Key Points: 
  • To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.
  • This training program is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology.
  • This initiative is designed to integrate genetics and genomics into patient care effectively, underscoring our dedication to enhancing genomic medicine worldwide.
  • Higgins, MD, MSHA, President of Brigham and Women’s Hospital and Executive Vice President at Mass General Brigham.